Merck continues to improve in the form of upgrading its production capacity. The German lab issued a press release last July explaining that it was investing 23 million euros to expand its Lenexa laboratory in Kansas.
Its US-based production facility is dedicated to the manufacture of cell culture powder and with this investment will add a total of 9100 square metres to the existing floor space.
Darren Verlenden, head of Merk's Life Science business, explained that this corresponds to one of the company's roadmap items: "The expansion of Lenexa reflects our commitment to meet the dynamic needs of our customers around the world and to deliver on our growth plans. This expansion makes Lenexa the company's largest dry powder cell culture media facility and Centre of Excellence in North America. Investing in the region reflects our strategy to expand and diversify our supply chain to ensure we meet current and future demand," the company's representative concluded in the statement.
Merck had already made effective investments for these means of cultivation in other countries, such as in China, in Nantong, with the aim of increasing local and global production capacity.
The statement was issued ahead of Merck's financial results for the first half of 2023, in which Merck reduced its sales and also its profit figure, which has forced the German company to recalculate its forecasts for the remainder of the year.